Two phase 3 trials of Merck & Co's Keytruda in metastatic castration-resistant prostate cancer (CRPC) and advanced liver cancer have ended in failure, proving once again that cancer immunotherapy ...

The FDA has started a priority review of MSD's Keytruda as neoadjuvant and adjuvant treatment of locally advanced head and neck squamous cell carcinoma (HNSCC), with a decision due by 23rd June.

Merck has filed a petition with the U.S. Patent and Trademark Office to challenge seven of Halozyme’s patents. Halozyme said ...

Most people receive Keytruda infusions for up to 2 years. But in some cases, treatment may last longer if there’s evidence that the drug is still effective and the side effects are minimal.

Keytruda (pembrolizumab) is prescribed to treat melanoma and other conditions by reviving the body’s immune system. Your response to this drug may vary based on your medical history, diagnosis ...

Lenvima plus Keytruda with TACE significantly improved progression-free survival in unresectable, non-metastatic hepatocellular carcinoma compared to TACE with placebo. The study reported a median ...